ProfileGDS5678 / 1416242_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 64% 66% 64% 64% 67% 65% 65% 65% 64% 64% 64% 65% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9422465
GSM967853U87-EV human glioblastoma xenograft - Control 23.8541164
GSM967854U87-EV human glioblastoma xenograft - Control 33.9647166
GSM967855U87-EV human glioblastoma xenograft - Control 43.790864
GSM967856U87-EV human glioblastoma xenograft - Control 53.8099664
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0807367
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9990165
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9347265
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9100165
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8589764
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8483264
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8302564
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9531865
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8518364